Celgene aims to boost the effectiveness of its novel drug marizomib for aggressive brain tumour glioblastoma (GBM) by asking patients to wear a special cap. Marketed by Novocure, the Optune device ...
Shares of NovoCure recently jumped in response to positive results from an important lung cancer trial. The company markets Optune, a battery-powered hat proven to suppress the growth of brain tumors.
Optune Lua adoption lag hit shares, but 2026 catalysts and $230M net cash could drive a rebound. Know more about NVCR stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback